FDA 483 - Daniel P Friedmann MD - January 16, 2020

The FDA inspected Daniel P Friedmann MD, a clinical investigator in Austin, TX, and observed a significant deviation from the investigational plan. The firm failed to perform required blinded evaluations for multiple subjects at various time points, including the primary endpoint, during a clinical study. This indicates a serious issue with protocol adherence and data integrity.